The ‘Biggest’ Dealmakers Of 2023 Were Not The Busiest

 
• By Joseph Haas

Eli Lilly, striving to outpace Novo Nordisk, dominated the dealmaking scene in 2023 by executing six acquisitions. Although Pfizer, BMS and AbbVie sealed the largest M&A deals of the year, they did not lead in terms of volume.

Deal making concept
The year’s biggest dealmakers – Pfizer, Bristol Myers Squibb and AbbVie – were not among the five busiest based on a review of dealmaking data • Source: Shutterstock

More from Deal-Making

More from In Vivo